CariDee English is blessed with long blonde hair and a beautiful, fresh, girl-next-door face. Chosen by CW Television in its “America's Next Top Model” competition, you will no doubt see the teen's photo on a magazine cover some day.

For now, CariDee is delighted to be the cover girl for a magazine far removed from “Seventeen” or ‘Vogue.” She is on the cover of the “National Psoriasis Foundation Journal” and has become a spokesperson for the organization. 

For the first extended period in her life, CariDee is now wearing shorts, showing off her long legs; legs that are finally clear. Psoriasis sufferers describe their skin as “clear” when it is free of the thickening, cracking and bleeding that accompanies a psoriasis flare-up. 

“My mother has psoriasis,” CariDee explains, “so she knew what it was as soon as my skin started to change. All I knew was that it itched and that because it was all over me I couldn't wear a bathing suit or even shorts. I couldn't go swimming because so many people look at someone with psoriasis and think they will infect everyone else. That's not true. You can rub against someone with psoriasis and not catch it. It's like a birthmark that way.” 

In spite of her severe psoriasis, CariDee had a dream of becoming a top fashion model. She has the face and the body to make the grade; her skin was the only thing stopping her. After years of working with a dermatologist and trying everything from creams to lotions to UV light therapy, she finally found something that controlled her psoriasis and cleared her skin. 

As a spokesperson for the National Psoriasis Foundation,, CariDee has since gone to Washington to lobby for more money to be allocated for education and research.

Facts and figures

Psoriasis is a chronic skin disease that affects more than 7 million people in America. Although the exact cause is unknown, most researchers agree that psoriasis is an immune-mediated disorder. In psoriasis, the immune system is somehow triggered, which in turn speeds up the growth cycle of skin cells.

A normal skin cell matures in 28 to 30 days and is shed from the skin's surface unnoticed. But a psoriatic skin cell takes only 3 to 4 days to mature and move to the surface where the cells pile up and form the elevated red lesions. 

Psoriasis appears to be slightly more prevalent in women than men and most commonly appears between the ages of 15 and 35. Nearly half a million new cases of psoriasis are diagnosed each year. Close to 40 percent of all psoriasis sufferers have one or more family members who also suffer from the disease. 

Psoriasis comes in various forms and levels of severity. By far the most common form is known as plaque psoriasis. Four out of five people with psoriasis have this type. “Plaque” is the name used to describe the patches of red, raised skin (also called lesions). The flaky, silvery white buildup on top of the plaques is called scale and is composed of dead skin cells. This scale comes loose and sheds constantly from the plaques, causing the affected skin to be very dry. 

In addition, other likely symptoms include skin pain, itching and cracking. Other forms of psoriasis are less common. Guttate psoriasis produces lesions that appear as small, red, individual drops on the skin. Inverse psoriasis is found in the armpits, groin, under the breasts and in other skin folds. This type of the disease appears as smooth, dry areas of skin that are red and inflamed but do not have the scaling associated with plaque psoriasis. It is more common and troublesome in overweight people.

Other forms of psoriasis (erythrodermic, pustular and acropustulosis) are even more rare.

Bad news, good news

First the bad news. The current opinion from the medical establishment is that psoriasis is a condition for which no treatment can offer permanent remission while maintaining the patient's quality of life. Most treatments available today offer only temporary remission and can generate significant side effects, including some with serious life-threatening impacts. According to a National Psoriasis Foundation survey, 78 percent of patients do not use more aggressive therapies because they fear side effects.

Now the good news. For the millions of Americans who suffer from psoriasis, there currently exists a natural medicine in capsule form that offers an alternative to presently existing treatment options such as creams, drugs and phototherapy. This formula is a patented, growth factors complex that holds the promise of becoming the best way to manage a condition for which, in the past, little could be done, and for which no treatment free of side effects has previously been developed.

The science behind the formula bears all the clinical and scientific credentials needed to also interest progressive medical doctors, especially dermatologists, who prescribe drugs but are also willing to use integrative and complementary approaches in their psoriasis treatment programs.

Available without a prescription, the formula is known as Dermalyx™ on the Freshlife shelves and BioDERM™ when purchased from a doctor. The difference is on the label only; the strength and dosage of the capsules is identical.

The science behind Dermalyx™

Psoriasis is an autoimmune disorder, which means that cell communication and proliferation within the immune system has gone awry. Growth factors and bioactive peptides are the naturally occurring molecules in the human body that modulate cell functions. Some of these growth factors and peptides inhibit the proliferation and differentiation of T-cells involved in the inflammatory process. It has been demonstrated that T-lymphocytes and the production of pro-inflammatory cytokines are key elements in the inflammatory process of immune-mediated inflammatory disorders such as psoriasis.

Dermalyx is a patented composition of growth factors comprised of TGF_2, among others, obtained from whey using a proprietary combination of physical and chemical treatments. Dermalyx also contains proteins such as beta-lactoglobulin, alpha-lactalbumine and lactoferrin, which have a marked impact on immune function. The active ingredient, XP-828L, appears to work well upstream on the entire immune system cascade by favorably down modulating pro-inflammatory Th1 cytokines.

Although the evidence is not entirely conclusive, genetic markers may affect the rate at which cells divide. This division is controlled by a delicate balance between cyclic adenosine monophosphate (AMP) and cyclic guanidine monophosphate (GMP). Levels of these two compounds are abnormal in people who suffer from psoriasis, causing psoriatic cells to multiply at a rate that is seven times faster than healthy skin cells. Rebalancing the cyclic AMP:GMP ratio is thus a therapeutic goal.

Whew! Sounds complicated, doesn't it? It is. You can share the more technical information with your dermatologist and understand simply that your skin is the largest organ of your body, containing literally trillions of cells. When your immune system is not communicating properly with these cells, the miscommunication can show up as the inflammation and cell overgrowth that are hallmarks of psoriasis. You can also rely on the results of the clinical trials that have been completed using Dermalyx.

The main criterion for measuring the formula's efficacy is the Psoriasis Area and Severity Index (PASI) score. PASI is a scientifically recognized measure of the average redness, thickness and scaliness of the lesions, weighted by the area of involvement. PASI improvement is the percent change in PASI score from Day 1. At day 28, 64 percent of the patients showed a reduction in their PASI scores relative to their baseline PASI scores at Day 1. These patients agreed to participate in the eight-week extension phase. At the end of the extended phase (112 days of treatment in all), the PASI score improvements for these patients ranged from 6.7 to 78.4 percent. A second study was conducted to confirm the efficacy and safety of Dermalyx on patients with mild-to-moderate psoriasis.

The randomized, double-blind, placebo-controlled 112-day study involved 84 patients and was conducted at two independent research centers by Dr. Robert Bissonnette, M.D., and Dr. Poulin, M.D., renowned dermatologists who have been involved in multiple clinical trials on psoriasis. More than 20 percent of patients had an average PASI improvement greater than 25 percent after 56 days with Dermalyx. Nearly 30 percent of the patients in the Dermalyx-treated group achieved a mean PASI improvement of 59 percent after 112 days.

New hope, real help

Dermalyx is newly available in the U.S. This patented and researched formula can be used for the treatment of mild-to-moderate psoriasis with or without other pharmaceutical drugs. If you suffer from psoriatic lesions, give the holistic program a try and discover why detoxification and Dermalyx is the best combination available to clinically manage the autoimmune condition known as psoriasis. Unlike CariDee English, you may not land a contract with Covergirl Cosmetics, but chances are you'll look and feel a whole lot better.

Health Disclaimer: The information provided on this site should not be construed as personal medical advice or instruction. It is intended for educational purpose only and is not meant to diagnose or treat any disease. No action should be taken based solely on the contents of this site. Readers should consult appropriate health professionals on any matter relating to their health and well-being. Site content is copyrighted and may not be reproduced without permission.